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The ‘asthma epidemic’ has led asthma to become the most frequent chronic disease among 
children in developed countries. However, the prevalence of asthma and allergic diseases 
varies greatly around the world, and despite extensive research, there has not been a 
significant breakthrough in the understanding of the mechanisms and genetics of, and 
effective preventive strategies for asthma. This thesis is based on the results from the study 
‘Asthma and allergy among schoolchildren in Nordland county’. Overall aims were to 
investigate prevalence of asthma, allergic rhinoconjunctivitis (AR) and eczema in 
schoolchildren, identifying risk factors and possible associative mechanisms for the 
development of asthma in children and the use of diagnostic tools in relation to asthma and 
allergic diseases. 
 
The first part of the study consisted of a cross-sectional questionnaire-based survey including 
4150 children aged 7-14 years from randomly selected schools in Nordland county. The 
results in 2008 were compared to the results from similar surveys in 1985 and 1995. In the 
second part of the study, children reporting asthma ever (cases) in the cross-sectional survey 
together with matched non-asthmatic controls were invited to participate in a case-control 
study. The case-control study consisted of the clinical assessment and extensive clinical 
testing of 801 children, and the results were partly compared to a similar case-control study in 
1985. 
 
The results demonstrated an increase in the prevalence of asthma and AR ever in 
schoolchildren in the period 1985-2008, while the prevalence of eczema ever reached a 
plateau. The prevalence of the current diseases doubled and trebled between 1995 and 2008. 
Compared to clinical assessment (gold standard) the survey questionnaire was found to have a 
high sensitivity (0.96) and specificity (0.87), together with a very good overall agreement. 
Exploring possible risk factors showed that lower respiratory tract infections (LRTIs), AR and 
food allergy were most important in 2008, while repeated LRTIs, atopic diseases in the family 
and urticaria ever had most impact in 1985. During the study period, increased average 
temperature may have led to a rise in pollen production and thereby the increased prevalence 
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of AR. Thus, AR might have contributed to the increased asthma prevalence in the study 
population 
 
In conclusion, the study revealed a considerable increase in the prevalence of asthma and AR 
in schoolchildren. When validating the questionnaire used against clinical assessment, we 
found the questionnaire to be a good epidemiological tool. LRTIs seems to be the most 
important risk factor for developing asthma in this subarctic child population, together with 
allergic comorbidity, which might have contributed to the increase in asthma prevalence in 






Astmaepidemien de siste årtiene, har ført til at astma er blitt den vanligste kroniske 
sykdommen blant barn i den vestlige verden. Selv om studier fra ulike steder viser stor 
variasjon i forekomsten av astma, allergisk øye- og nesekatarr (rhinokonjunktivitt) og eksem, 
har man på tross av utstrakt forskning ikke funnet årsaken til sykdommene eller entydige 
forebyggende tiltak. Denne avhandlingen (tesen) er basert på resultater fra studien ‘Astma og 
allergi blant skolebarn Nordland’. Formålet med studien var å undersøke forekomsten av 
astma, allergisk rhinokonjunktivitt og eksem blant skolebarn, identifisere risikofaktorer og 
mulige assosiative mekanismer for utviklingen av astma samt evaluere diagnostiske metoder 
brukt for astma og allergiske sykdommer.  
 
Første del av studien bestod av en tverrsnittstudie som inkluderte 4150 barn, 7-14 år gamle fra 
tilfeldig utvalgte skoler i Nordland fylke. Resultatene fra 2008 ble sammenlignet med 
resultatene fra lignende studer fra 1985 og 1995. I den andre delen av studien ble astmatiske 
barn (cases) fra tversnittstudien invitert sammen med ikke-astmatiske barn (controls) med 
samme kjønn og alder til en oppfølgende case-control studie. Case-control studien bestod av 
klinisk vurdering og utstrakt klinisk testing av 801 barn, og resultatene ble delvis 
sammenlignet med en lignende case-control studie fra 1985.  
 
Resultatene fra studien viser en økning i forekomsten av astma og allergisk rhinokonjunktivitt 
mellom 1985 og 2008, mens forekomsten av eksem flatet ut i siste del av perioden. 
Forekomsten av sykdom siste år, doblet og tredoblet seg mellom 1995 og 2008. 
Sammenlignet med klinisk vurdering (som gullstandard) hadde spørreskjemaet som ble brukt 
i studien høy validitet (sensitivitet 0.96 og spesifisitet 0.87) og resultatene var samsvarende. 
Undersøkelsen av mulige risikofaktorer for astma viste at nedre luftveisinfeksjoner, allergisk 
rhinokonjunktivitt og matvareallergi var viktigst i 2008, mens gjentatte nedre 
luftveisinfeksjoner, atopisk sykdom i familien og elveblest hadde størst betydning i 1985. I 
løpet av studieperioden har sannsynligvis en økning i gjennomsnittstemperatur ført til økt 
pollen produksjon og økt forekomst av allergisk rhinokonjunktivitt. Det kan bety at allergisk 
rhinokonjunktivitt har bidratt til økningen i astmaforekomst i denne populasjonen. 
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Som en konklusjon viser studien en kraftig økning av forekomsten av astma og allergisk 
rhinokonjunktivitt, og at spørreskjemaet fungerer som et godt epidemiologisk verktøy. Nedre 
luftveisinfeksjon ser ut til å være den viktigste faktoren for utvikling av astma i denne 
barnepopulasjonen, sammen med allergiske sykdommer. Allergisk rhinokonjunktivitt kan ha 
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1.1.  The ‘asthma epidemic’ 
Asthma is recognised as a complex condition with differences in severity, natural history, 
comorbidities, and treatment response (1). In recent decades, the prevalence of asthma and 
allergic diseases has increased substantially. The upward trend in asthma prevalence has been 
termed the ’asthma epidemic’ (2). This ‘asthma epidemic’ has led asthma to become the most 
frequent chronic disease among children in developed countries (3, 4). Even if asthma-related 
hospitalisations and deaths have declined, the disease globally imposes a considerable burden 
on patients, healthcare systems and societies (5). Decades of research have not resulted in a 
significant breakthrough in the understanding of the mechanisms, genetics and possible 
preventive strategies of asthma (6).  
 
1.2.  Asthma definition  
Asthma as a medical term was probably first used by Hippocrates (460-370 BC) (7). Since 
then the disease has been described in a multitude of ways based on the current knowledge of 
the time and the most recent understanding of pathogenesis, underlying mechanism and 
possible causal factors. As an attempt to make international guidelines based on consensus the 
Global Initiative for Asthma (GINA) was founded in 1993 (8). Over the past 25 years, GINA 
has published and annually updated the ‘global strategy for asthma management and 
prevention’. This has formed the basis for many national guidelines (9). In 2014, the 
definition of asthma was revised with the purpose of making it more applicable to clinical 
practice. In the 2018 updated GINA guidelines the current definition is: 
 ‘Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. 
It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest 
tightness and cough that vary over time and in intensity, together with variable expiratory 
airflow limitation’ (10).  
 
1.3.  Clinical features of asthma  
Both symptoms and airflow limitation characteristically vary over time and in intensity. These 
variations are often triggered by external factors such as viral respiratory infections, allergens 
or irritant exposure, changes in weather conditions and exercise. Despite the childhood 
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asthma spectrum being well recognized (11), subgroups are challenging to identify and the 
number and definitions of asthma types are unknown. Later descriptions refer to asthma as an 
umbrella term like anaemia or arthritis (1, 12), which may identify syndromes, phenotypes or 
even multiple diseases rather than a single disease (figure 1). Recognisable clusters of 
clinical, demographic and/or pathophysiological characteristics with identifiable biomarkers, 
risk factors, comorbidities and response to therapies are often called ‘asthma phenotypes’. 
However, these subgroups do not necessarily correlate with specific pathological processes or 
treatment responses (13). In addition, several of the phenotypes overlap (12) making sub-
classification complicated.  
 
 
Figure 1. Schematic presentation of the umbrella term ‘asthma’.  
The key clinical features of severity (lung function, symptoms and exacerbations), 
inflammatory characteristics (particularly TH2 immunity) and their division into 
associated phenotypes are shown. However, these phenotypes have not yet been fully 
characterized. 
 
Reprinted by permission from (12). © 2012 Nature America, Inc. All rights reserved. 
 
Asthma has different degrees of severity (14). Most children suffering from asthma have mild 
to moderate symptoms and are able to control the disease by using inhalation medicines (i.e. 
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short acting β2-agonists and inhaled corticosteroids (ICS)). However, a small fraction, 
estimated prevalence 4-5% of the children with current asthma (15), experience serious illness 
with symptoms during the night, frequent periods of exacerbations, numerous absences from 
school, reduced quality of life and increased risk of hospitalisation. Children suffering from 
sever asthma often do not respond to standard therapy and are therefore difficult to treat 
properly. Another feature of asthma is that many patients experience relapse after years 
without symptoms, which illustrates the importance of long-term follow-up (16). 
 
1.4.  Different epidemiological study designs 
Epidemiology is the study of something that afflicts a population. Usually epidemiology is 
defined as the study of factors that determine the occurrence and distribution of disease in a 
human population (17). The central goal of epidemiology as a science is to understand the 
causes of disease variation and use this knowledge to improve the health of populations and 
individuals. Traditionally epidemiological research has consisted of observational studies 
where the investigator is not acting upon study participants (18). However, it has become 
more common to include intervention studies as part of epidemiological (clinical) research.  
 
As many research questions can be answered by different type of study design, the choice of 
design depends of several considerations, including speed, costs, resources, access to cases 
and identification of the exposures. Each type of design has advantages and disadvantages, as 
summarized in table 1. Prospective cohort studies are considered the gold standard of 
observational studies being the only design suited for suggesting causation (18). In contrast, 
case-control studies compare exposures between people with a particular disease outcome 
(cases) and people without that outcome (controls). The longitudinal design makes is possible 
to measure the incidence and the natural history of disease.	One of the most important 
principle in case-control studies is that the controls should represent the population at risk of 
the disease (19).  
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Table 1. Advantages and disadvantages in different designs used in epidemiological studies. 





Can assess multiple outcomes 
Can calculate prevalence 
Carried out at a singled point in time 
Do not offer a temporal relationship between 
risk factors and disease 
Cohort studies Can be performed retrospectively or 
prospectively 
Can be used to obtain a incidence and a 
true measure of risk  
Can assess multiple outcomes 
Time consuming 
Prospective studies are costly  
Can only study risk factors included from 
the beginning 
Losses to follow-up 




Quick and easy to perform. 
Can assess multiple exposures or risk 
factors 
Good for rare diseases 
Can obtain only a relative measure of risk  
Subjected to selection and recall biases  




Evaluation of treatments and 
interventions (gold standard) 
Time consuming 
Expensive 
Limited in generalizability  
 
Research has demonstrated a lack of consistency in reporting on quality in observational 
studies published in high impact medical journals (20). Consequently, the STROBE initiative 
was set in form of a checklist with the aim to provide helpful recommendations for reporting 
epidemiological studies to improve the reporting quality (21).  
 
1.5.  Asthma screening  
The best evidence of changes in disease prevalence comes from repeated studies in the same 
population at sufficient intervals of time and using the same instrument (2, 22). Screening is 
defined as ‘examination of a group of usually asymptomatic people to detect those with a high 
probability of having a given disease, typically by means of an inexpensive diagnostic test’ 
(23). Validity is the degree to which an instrument measures what it intends to measure. 
While no screening test is perfect, valid prevalence estimates require a screening test with a 
high sensitivity and specificity (24). Sensitivity is the proportion of subjects with ‘true’ 
asthma and specificity is the proportion of subjects without asthma classified correctly by the 
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survey instrument. In the absence of an unambiguous definition of asthma and a diagnostic 
‘gold standard’, clinical assessment is the closest we can get to a true diagnosis (25, 26).  
 
An important challenge with symptoms-based questions is to identify asthma as distinct from 
other diseases presenting with similar symptoms. The symptom ‘wheeze’ is a hallmark of 
early childhood asthma and is used as a proxy marker to determine asthma prevalence in 
population surveys (27). Still, there are several causes of ‘wheeze’ other than asthma, for 
instance lower respiratory tract infections (LRTIs) and poor physical condition. In addition, 
wheeze is a fluctuating symptom with varying duration, and using wheeze in computing the 
incidence of childhood asthma might result in over-estimating (28). Furthermore, the lack of 
an exact translation of the term ‘wheeze’ in most languages (25) may entail some uncertainty 
around the interpretation of the results. Thus, parental reported ‘wheeze’ carries a large risk of 
misclassification and lacks cross-cultural validity (27, 29).  
 
Efforts have been made to increase the diagnostic accuracy of childhood asthma by adding 
objective measurements such as lung function tests and tests of bronchial hyper-
responsiveness (BHR). These tests provide objective information, which does not change over 
time, an advantage that can be exploited in repeated studies. On the downside, clinical tests 
are	difficult to perform in large populations and results from several studies demonstrate that 
these measurements	do not necessarily provide additional information (22, 30, 31). 
	
The majority of published data concerning the prevalence of asthma and temporal time trends 
are based on repeated cross-sectional questionnaire studies, such as the International Study of 
Asthma and Allergies in Childhood (ISAAC) (32) and The Obstructive Lung Disease in 
Northern Sweden (OLIN) study (33), together with other studies from Sweden (34), Canada 
(35), Greece (36) and Italy (37). In addition, knowledge about asthma prevalence has been 
brought to us by prospective cohort studies using repeated questionnaires like the Tucson 
Children’s Respiratory Study (TCRS) (38), the German Multicentre Allergy Study (MAS) 
(39), the Environment and Childhood Asthma (ECA) study in Oslo (40), the Barn (Children), 
Allergy, Milieu Stockholm Epidemiological Study (BAMSE) (41) and the Copenhagen 





1.6  Asthma prevalence and temporal trends 
In the northern part of Norway, a questionnaire-based, cross-sectional survey focusing on 
asthma, allergic rhinoconjunctivitis (AR) and eczema was conducted in 1985 (43) (Appendix 
1). The questionnaire was distributed to schoolchildren aged 7 -13 years in randomly selected 
schools in northern Norway (Nordland, Troms and Finnmark counties) for parental/guardian 
reply. Altogether, 10 093 (90.1%) children responded. Ten years later a similar questionnaire 
with additional questions concerning symptoms and diseases during the last 12 months 
(current diseases) was sent to schoolchildren in the same geographical area (Appendix 2). A 
total of 8676 (87.3%) responded in Nordland county and the lifetime prevalence of asthma 
increased from 5.1% to 8.6% over this 10-year period (44). The questionnaire has been used 
in other surveys in Norway (45-47). 
 
In 1993, the ISAAC study created a cross-sectional questionnaire based trial to maximise the 
value of epidemiological research in asthma and allergic diseases (32). Compared to the 
questionnaire created in northern Norway, the ISAAC questionnaire constituted similar 
questions. The main difference between the ISAAC questionnaire and the questionnaire 
created in Norway was he question about asthma symptoms. In this question, the ISAAC only 
asked about wheeze or whistling (Question 1, table 1) (32), while the Norwegian 
questionnaire (Question 2 in definition of asthma ever) in addition asked about shortness of 
breath and cough. The ISAAC Phase I results presented in 1998, revealed an up to 20-fold 
variation in the prevalence of ‘current wheeze’ between more than 60 centres worldwide 
(range 1.8-36.7%) (48). The highest prevalences were detected in developed English-speaking 
countries (e.g. UK, Australia and New Zealand), while the lowest prevalences were found in 
Eastern Europe and Asia (i.e. India and China). Results from the ISAAC Phase III study 
(2000-2003) indicated that wide variation in asthma symptom prevalence still existed even if 
the difference in asthma symptom prevalence between developed and developing countries 




Figure 2. The worldwide prevalence of current asthma symptoms among 13-14 year olds 
(ISAAC).  
The prevalence of current wheeze according to the written questionnaire in the 13–14 year 
age group in ISAAC, phase III.  The symbols indicate prevalence values of <5% (yellow 
square), 5 to <10% (blue circle), 10 to <20% (purple diamond) and >20% (red star). 
 
Reprinted by permission from (51). © 2009 BMJ Publishing Group Ltd and the British 
Thoracic Society. All rights reserved. 
 
Other estimates of temporal trends in asthma prevalence are conflicting. Whereas some 
studies performed in the period from 1995 until present demonstrate an increasing prevalence 
of asthma and allergic diseases (35, 52, 53), other reports indicate a levelling off or even a 
decrease in asthma prevalence (54-56). These diverse global trends make repeated regional 
investigations important to assess time trends. Local surveys provide information about 
geoclimatic variables and topographical factors that may affect disease prevalence (57, 58).  
 
1.7.  The ‘atopic march’ and asthma comorbidity  
Allergy-related or atopic diseases, includes asthma, AR, eczema and food allergy. Atopy is 
defined as ‘a personal or familial propensity to become sensitised and produce 
immunoglobulin E (IgE) antibodies in response to environmental triggers’ (59). The diagnosis 
of allergic diseases involves both the presence of symptoms and relevant sensitisation. 
Allergic diseases share several characteristics and are all included within the ‘atopic march’. 
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The ‘Atopic March’ sometimes called the ‘Allergic March’ refers to the natural history or 
typical progression of allergic diseases, which often begins early in life (60). Eczema in the 
form of atopic dermatitis defines the initial step of the atopic march and is a significant risk 
factor for the development of asthma and AR, but whether atopic dermatitis is necessary for 
progression to other atopic diseases, remains to be established (61).  
 
Food allergy is an adverse health effect arising from a specific immune response that occurs 
reproducibly after exposure to a given food, including both IgE mediated or non-IgE 
mediated reactivity (62). Food allergy is more prevalent in early childhood. The prevalence of 
food allergy has increased during recent decades, in the same manner as asthma prevalence 
(63). In the USA, the prevalence of food allergy overall was found to be 8% in children (0-17 
years) (64). The National Health and Nutrition Examination Survey 2005-2006 (USA) 
showed that study participants with doctor-diagnosed asthma (versus no asthma), particularly 
those reporting current asthma, exhibited increased risk of allergic sensitisation towards food 
and increased risk of likely food allergy (65).  
 
The link between AR and asthma is well known and they frequently coexist. In the 
Norwegian ECA study, current rhinitis was reported in 25.0% of the 10-year-old children and 
was associated with asthma in 31.7% of the children (66). Investigating the association 
between asthma and other diseases using healthcare data from children and adolescents (6-17 
years of age) in Germany, Jacob and colleagues revealed a strong association between asthma 
and vasomotor rhinitis and/or AR (OR 4.5-5.9) (67). In asthmatic children, 55-80% are 
reported to suffer from comorbid rhinitis in other studies (68-70). Asthmatic children 
suffering from AR have poorer asthma control (69) and experience more severe asthma 
symptoms, and more asthma exacerbations resulting in more absence from school (71).  
 
Several studies have recorded a substantial degree of comorbidity between asthma, AR and 
eczema. The BAMSE study in Sweden showed that comorbidity between asthma, eczema and 
rhinitis increased from 1.8% at 1 year of age to 7.5% at age 12 (70). A prospective cohort 
study assessing children from 12 ongoing European birth cohort studies (Mechanisms of the 
Development of Allergy (MeDALL)) pointed out that coexistence of eczema, rhinitis, and 
asthma in the same child was more common than expected, regardless of IgE sensitisation 
(72). Other diseases e.g. pneumonia, chronic bronchitis and obesity, have also been found to 
be associated with asthma (67). 
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1.8.  Risk factors for childhood asthma 
Asthma is a complex disease. It is likely that changes in prevalence are due to multiple factors 
each contributing a relatively small effect (2, 73, 74). Numerous theories have been launched 
in order to explain the increased prevalence of asthma and allergic diseases. However, a truly 
unifying concept is still missing. Much attention has been devoted to the hygiene hypothesis. 
The epidemiologist D. Strachan proposed the hygiene hypothesis in 1989, which suggested 
that the rise in prevalence of allergic diseases could be explained by reduced opportunities for 
cross-infection in young families (75). According to the hygiene hypothesis, a reduction in the 
diversity and magnitude of ‘microbial burden’ in early life decreases activation of a common 
immune control mechanism, namely regulatory T-cells. The reduction in control mechanism 
leads to a increased propensity for allergy sensitisation (76). Later research has concluded that 
the original hygiene hypothesis based purely on infection, does not offer a complete 
explanation of the observed increase in allergic diseases (77). 
 
The wide variation in asthma prevalence between populations and the rapid rise within a 
relatively short period indicate that environmental factors play a greater role than genetic 
factors (2). In contrast to this assumption, parental asthma and/or AR often are the strongest 
risk factors compared with other risk factors in epidemiological studies (58, 78-80). Other 
individual risk factors are: maternal smoking, gender, AR, allergic sensitisation, birth weight, 
family stress at birth, overweight, LRTIs, length of breastfeeding, household animals, lifestyle 
and living conditions (80-83). In addition, some environmental factors at the population level, 
such as climate changes and outdoor pollution may affect the development of asthma (84-86).  
 
1.8.1. Non-Environmental risk factors 
Allergic sensitization   
The prevalence of allergic sensitisation increases during childhood and adolescence, usually 
starting with sensitisation to food allergens and thereafter sensitisation to inhalant allergens, 
until the prevalence levels out in early adulthood (52, 87, 88). Some risk factors for allergic 
sensitisation are known, and heredity seems to be the strongest factor (89). Allergic 





Birth weight and overweight 
Birth weight is a proxy marker for the environment in utero. Low birth weight because of 
poor intrauterine growth (small for gestational age) and low gestational age at birth seem to 
be risk factors for later asthma (91-93). The increase in asthma and allergic diseases has 
occurred in parallel with the obesity epidemic, suggesting a possible association. However, 
studies in children concerning weight and the risk for developing asthma have not been 
consistent. It appears to be a U-shaped association between body mass index (BMI) and risk 
for asthma (94, 95). Some have documented a stronger association between obesity and 
asthma in those with no allergy history, implying that a distinct obesity phenotype may 
explain the diversity in study findings (96). 
 
Genetics 
Asthma and allergic diseases has a strong heritable component (97), and in epidemiological 
studies (58, 80), parental asthma is the strongest risk factor. Several genes (>100) with a 
positive association to asthma or atopic phenotypes have been identified, even though the 
individual effect of any one of these genes on disease risk is quite small (98, 99). Recently, 
there has been increased attention on the link between genetics and environmental factors: 
epigenetics. Epigenetics is the study of heritable changes in gene expression or cellular 
phenotype caused by mechanisms other than changes in the underlying DNA sequence (100). 
Epigenetics may partly explain the heterogeneous appearance of asthma, but further studies 
are needed to determine its role in its development.  
 
Sex 
It is well known that the prevalence of asthma and asthma symptoms differs between males 
and females. Until teenage, the prevalence of asthma is higher among boys than girls. Studies 
reporting sex-specific time trends document a change to a female predominance in the sex 
ratio during puberty and adolescence (28, 56, 101, 102). At which age this shift take place has 
been debated. A recent study indicated this breaking point to be around 15 years of age (103). 
One of the reasons why the male disadvantage for asthma disappears during puberty seems to 
be a higher remission rate among boys than girls (104). Hormonal influences (105) and 





1.8.2. Environmental risk factors 
Breastfeeding  
Breastfeeding is an important factor that has been linked to childhood asthma. Although many 
health benefits of breastfeeding are well documented, studies reporting effects on asthma risk 
have inconsistent findings. Both the Swedish BAMSE and Danish COPSAC studies have 
demonstrated a protective effect of breastfeeding on the development of asthma (106, 107), 
while a randomised trial among nearly 14 000 children receiving an experimental 
breastfeeding intervention and followed up until age 6.5 years, showed no differences in 
asthma prevalence or allergic symptoms between the groups (108). Recent studies suggest 
that the efficacy of the World Health Organization (WHO) breastfeeding guidelines relating 
to long-term outcomes for allergic disease might be questioned (109). 
 
Climate change and outdoor pollution 
Despite efforts to link the ‘asthma epidemic’ to climate change and increased outdoor 
pollution, it has been difficult to document a definitive association between air pollution and 
asthma development. The global patterns of asthma prevalence contradict the hypothesis that 
air pollution is a major risk factor for the development of asthma, since regions with the 
highest level of traditional air pollution (e.g. China and Eastern Europe) have considerable 
lower asthma prevalence than regions with lower air pollution (i.e. Western Europe, Australia, 
North America) (110). Still it is questioned if traffic-related air pollution has an impact on 
asthma development alone or in combination with genetics, allergens, tobacco smoke and 
psychosocial stress (2). 
 
The ISAAC Phase one study has demonstrated a negative association with annual variation of 
temperature, relative humidity outdoor and childhood asthma symptoms in Western Europe 
(111). These results suggest that climate might affect the prevalence of asthma (112). A 
possible explanation for this phenomenon is that the generation and dispersion of air 
pollutants depend in part on local patterns of temperature, wind, solar radiation and 
precipitation. Thus, climate changes influence air quality and outdoor air pollution levels, 





Figure 3. Climate change: its influence on extreme weather events, air pollution and 
aeroallergens, and effects on respiratory health.  
PM: particulate matter; COPD: chronic obstructive pulmonary disease. 
 
Reprinted by permission from (113). ©ERS 2013. All rights reserved. 
 
Early life infections 
LRTIs caused by viruses are major triggers for wheeze and asthma exacerbations, especially 
in infants and young children. Rhinoviruses are the most prevalent viruses detected in all age 
groups, while Respiratory Syncytial Virus (RSV) is the most common cause of severe 
bronchiolitis in infants (114, 115). Viral airway infections and atopy may interact in a 
multiplicative way to promote asthma development in young children. Since early infancy 
constitutes a particularly vulnerable period of life, a causal relationship has been suggested, 
but not established, between LRTIs and asthma (116, 117). On the other hand, virus induced 
wheeze may uncover a predisposition for asthma development followed by impaired lung 
function (11). The number and severity of early life bronchial obstructive episodes have the 
greatest impact on risk of pubertal asthma (82). 
 
Environmental tobacco smoke exposure (ETS) 
ETS during pregnancy is a known risk factor for the development of asthma and is associated 
with a lower birth weight, decreased lung function and an increased risk for wheezing (118). 
Recent reports imply that an association between parental smoking and childhood asthma 
extends further, beyond maternal smoking during pregnancy and throughout childhood (112, 
119). The OLIN studies demonstrated a 50% decrease in the prevalence of maternal smoking 
from1996 to 2006, diminishing the impact on current asthma to near zero (58). Decreasing 
ETS will probably positively influence the development of asthma and asthma symptoms. 
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Exposure to animals  
The most commonly studied associations between animal exposure and asthma are exposure 
to cats and dogs; the most commonly kept household animals in the western world. In a meta-
analysis including data from both cross-sectional and cohort studies from 1966 to 2007, 
Takkouche and colleagues found that exposure to cats exerted a preventive effect on asthma 
while exposure to dogs increased the risk of asthma (120). In a more recent report from the 
ISAAC Phase 3 study, it was concluded that exposure to cats in the first year of life was a risk 
factor for symptoms of asthma, AR and eczema in children aged 6 -7 years (121). One 
challenge in interpreting the results from these studies is that families with asthma and 
allergic diseases might refrain from having pets at home or might remove them after disease 
has been established. This could lead to the erroneous conclusion that pet ownership provides 
a protective effect (reverse causation) (122).  
 
Another important association is the allegedly protective effect of being exposed to farming 
environments and farm animals. Two large-scale observational studies of schoolchildren 
living in predominantly rural areas of Central Europe (PARSIFAL and GABRIELLA) 
compared children living on farms with a reference group. Both studies came to the same 
conclusion: Children living on farms were exposed to a wider range of microbes than children 
in the reference group. The exposure to a wider range of microbes could explain a substantial 
fraction of the inverse relation between asthma prevalence and growing up on a farm (123).  
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2. Aims of the thesis 
 
The overall aim of ‘Asthma and allergy among schoolchildren in Nordland county’ was to 
investigate:  
• The occurrence and time trends of atopic diseases in a subarctic child population 
• Factors that may influence the degree of severity and course of bronchial asthma 
• Underlying risk factors and possible associative and causal mechanisms for the 
development of asthma among schoolchildren 
• Fractional exhaled nitric oxide (FENO) levels in relation to asthma, AR, serum specific 
IgE (sIgE) and exercise and establish cut-off levels for sIgE to diagnose AR.  
 
The specific aims in this thesis were: 
 
1. To explore whether or not the prevalence of asthma, AR and eczema in schoolchildren in 
Nordland county continued to increase over a 23 year period (paper I). 
 
2. To validate the questionnaire used in paper I and make an assessment of its reliability and 
practical usefulness (paper II). 
 
3. To explore associative and possible risk factors for asthmatic disease in this child 
population and compare the results with data from 1985: can transformation of risk factors 
explain altered prevalence of asthma and/or local conditions that may have affected 










3.1.  Study area 
The Northern part of Norway consists of three counties: Nordland, Troms and Finnmark, with 
a subarctic population of 485 000 inhabitants. Nordland county, which covers an area of 38 
000 km2 has a population of 243 000 (124). Its unique geography features a long coastline 
(25% of Norway’s total coastline), half of it located north of the Arctic Circle. Thus, most of 
Nordland’s inhabitants live in sparsely populated areas and experience a coastal climate. 
 
3.2.  Overall study design  
 This thesis is based on data from a cross-sectional survey and a case-control study from 
‘Asthma and allergy among schoolchildren in Nordland county’, together with data from 
previously published cross-sectional surveys in 1985 and 1995 (paper I) and from a 
previously unpublished case-control study performed in 1985 (paper III). The overall study 
design in ‘Asthma and allergy among schoolchildren in Nordland County’ and in the 1985, 
study follows a similar pattern (figure 4):  
1. A cross-sectional survey. 
A questionnaire for determining the prevalence of asthma, AR and eczema was 
distributed to randomly selected schoolchildren. All surveys compared used identical 
questions for defining disease.  
2. A case-control study 
Study subjects who reported ever having asthma (cases) together with matched non-
asthmatic controls were invited to a case-control study including a new questionnaire, 
a structured interview and clinical examination and testing. Based on the clinical 
assessment (interview and clinical examination) children were categorised as 
asthmatic or non-asthmatic and asthma severity was classified. 
3. Study subjects fulfilling the definition criteria for current asthma (cases) and non-




Figure 4. A schematic flow chart for study subjects in ‘Asthma and Allergy among 
schoolchildren in Nordland County.  
aSubjects categorised as non-asthmatic after clinical assessment. 
bSubjects misclassified as non-asthmatics, new cases of asthma. 
 
The matched case-control design was chosen over the preferred prospective cohort 
(longitudinal) design due to limited resources for conducting the study, the timeline and since 
we aimed to validate the questionnaire used in the cross-sectional survey, evaluate different 
diagnostic tools and assess associations between asthma and different exposures. The main 
reason for choosing a matched design was to ensure that the cases and control were similar 
with respect to the possible confounding factors age and gender. Age and gender are both 
strongly associated with the outcomes asthma, AR and eczema together with several of the 
exposure variables. Matching for these variables, we believe, ensured better statistical 





3.3.  Ethical considerations 
Children as study subjects are vulnerable since they cannot give their own, independent 
consent to participating. Hence, when conducting research in children one must be very 
careful in the consideration of ethical aspects. In the cross-sectional survey, the 
parents/guardians signed a written consent for their children’s participation. In addition, they 
gave a written response to the question: Do the parents allow us to contact you with 
information on a follow-up survey if your child is selected to participate? Only individuals 
who answered yes to this question were invited to the case-control study. At enrolment, a 
renewal of the consent was obtained from all the participating children and their 
parents/guardians. The participants were informed that they could withdraw from the study at 
any time. 
 
Written information about risks and benefits for the study participants was sent together with 
the invitation to the case-control study. When the children met for their assessment and 
examinations, the risks and benefits for the participants were repeated verbally to the child. 
Since participating was voluntary, the children could withdraw from any part of the study if 
desired. The main risks for participating in the case-control study were sharing sensitive 
information with the researchers and experiencing discomfort from some of the tests (e.g. 
blood sampling). The benefits of participating in the study were a thorough clinical 
assessment of their asthma, AR and eczema status, extensive examinations using different 
diagnostic tests and gaining information about the diseases and evaluation of treatments as 
adding or discontinuing medication. All participants examined with blood sampling received 
a letter containing the test results with comments, after analysis.  
	
At enrollment, each participant received a unique record id number to secure anonymity and 
making any tracing of the participants impossible for unauthorized people. In order of 
combining record id numbers to names at follow up, a key only known to the two main 
researchers in the study was used. The anonymous data was stored in a separate computer 
with login and password. Later, the data files were sent for secure storage at Nordland 
Hospital Trust. 
 
The Regional Committee for Medical and Health Research Ethics, Northern Norway and the 
Norwegian Data Inspectorate approved both the study in 1985 and to ‘Asthma and allergy 
	 31	
among schoolchildren in Nordland County’. In ‘Asthma and allergy among schoolchildren in 
Nordland County’, Health Research Ethics were conducted in accordance with the ethical 
standards of the 2000 Helsinki Declaration. All written documents and questionnaires from 
the study was shredded and an end report of the study has been sent to the Norwegian Data 
Inspectorate. 
 
3.4.  The 1985-study 
Two paediatricians Jan Holt and Roald Bolle developed a questionnaire concerning asthma, 
AR and eczema and used it for the first time in 1985 (Appendix 1). The questionnaire was 
distributed to randomly selected schoolchildren in Northern Norway aged 7-13 years. In 
1995, the survey was repeated (43, 44) (paper I) (Appendix 2). From the survey in 1985 
approximately one third of the children reporting asthma ever (those with birthdays between 
the first to tenth of every month) together with non-asthmatic controls matched for age, 
gender and school affiliation, were invited to participate in the case-control study during 
1986-1987. The children lived in different geographical areas in Nordland, representing both 
coast and inland. 
 
Participating children with parents/guardians completed a structured interview including 
questions concerning socio-economic conditions, LRTIs, passive smoke exposure, and 
detailed questions about asthma symptoms and treatment. In addition, the participants 
underwent a clinical examination and clinical testing including spirometry and sIgE. SPTs 
were performed in cases only. A modified Kjell Aas scale, a system proposed by Norwegian 
paediatric allergologist (45) was employed for the evaluation of severity. A paediatrician, Jan 
Holt, conducted all interviews, examinations and tests at the local healthcare station or in the 
children’s homes. Data from this case-control study are previously unpublished (paper III).  
 
3.5.  Asthma and allergy among schoolchildren in Nordland county 
To identify symptomatic and non-symptomatic children suffering from atopic diseases, 
schoolchildren aged 7-14 years from 65 randomly selected schools of the 244 schools in 
Nordland county were invited to participate in a cross–sectional questionnaire-based survey. 
Parents and children received a questionnaire with identical questions for defining disease 
(asthma, AR and eczema) as in the 1985 and 1995 surveys (Appendix 3). The questionnaire 
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was distributed between February and May 2008. All participants received one reminder. The 
study closed four weeks after the reminder was distributed (paper I).  
 
To validate the questionnaire and to verify diagnosis and risk factors for atopic diseases, we 
performed a case-control study. Pupils who reported asthma ever (cases) in the questionnaire 
and who lived within two hours by car from the study locations along with two matched non-
asthmatic controls were invited to participate. The cases were matched to non-asthmatic 
controls on an individual basis for gender and age, choosing the non-asthmatic child closest in 
age. Preferably, cases and controls went to the same school; however, when this premise was 
violated due to the small number of pupils at the school, the control was chosen from the 
same geographic area.  
 
The children, together with their parents or guardian, completed a questionnaire and a 
structured interview. A clinical examination, spirometry, exercise treadmill testing, skin prick 
tests (SPTs) and measurements of FENO, sIgE and total IgE were obtained. Based on the 
clinical assessment (interview and clinical examination) as the golden standard, children were 
finally categorised as asthmatic or non-asthmatic (paper II).  
 
The asthmatic children were categorised as current asthmatics or not, and asthma severity was 
classified according to the GINA guidelines (14). The assessments of children fulfilling the 
definition criteria for current asthma and non-asthmatics age- and gender-matched controls 
were compared (paper III). 
 
The participants were examined at least two weeks after any suspected respiratory tract 
infection during the school term from March 2009 to June 2010. The examination took place 
at Nordland Hospital Trust, Bodø, and three other locations in Nordland county (Fauske, Mo i 
Rana and Sortland). Bjørg Evjenth MD, Phd and the author conducted all the interviews and 








3.6.  Definitions 
3.6.1. The cross-sectional survey (paper I) 
'Asthma ever' was considered if the parent answered 'yes' to the question: Has the pupil ever 
had asthma? and/or to the question: Does the pupil experience wheeze, periods of coughing or 
acute shortness of breath (asthma) due to external factors?  
ʹAllergic rhinoconjunctivitis (AR) everʹ  was based on a positive answer to the question:  Has 
the pupil ever had hay fever (runny or blocked nose, sneezing, itching of the nose and/or eyes, 
or swollen or red eyes)?  
ʹEczema everʹ  was recorded if the pupils reported an itchy rash lasting at least four weeks 
combined with lesions on the face, elbows or knee flexures, or a high degree of itching and 
lesions elsewhere.  
ʹCurrent diseaseʹ  was considered among those answering yes to the main questions about 
asthma, AR or eczema and reporting symptoms the last 12 months. 
 
3.6.2. The case-control studies (paper II and III) 
Based on the structured interviews and clinical findings, the final diagnoses in the surveys 
were confirmed by a doctor.  
Asthma: At least two of the following three criteria fulfilled at any time in life: 1) recurrent 
dyspnoea, chest tightness and/or wheeze; 2) a doctor’s diagnosis of asthma; 3) Use of asthma 
medication including β-2 agonist, sodium chromoglycate, ICS, leukotriene antagonists and/or 
aminophylline. 
Current asthma: asthma as defined above, plus symptoms and/or medication within the last 
year.  
Allergic rhinoconjunctivitis (AR): a history of watery rhinorrhea, blocked nose, sneezing, 
nasal itching accompanied by itchy watery eyes in the absence of airway infection.  
Eczema: an itchy rash lasting at least 4 weeks combined with lesions on the face, elbows or 
knee flexures, or a high degree of itching and lesions elsewhere. 
Food allergy: a history of related food allergy symptoms as evaluated by a doctor. 
Current disease: symptoms as defined above within the last year. 
Atopic disease in the family: a positive response to the question: ‘Does anyone in the family 
(parents and/or siblings) suffer from asthma, AR, eczema or urticaria’. 
Allergic sensitisation: a positive SPT (wheal diameter ≥3 mm larger than the negative 
control) and/or a positive sIgE (>0.35 kU/L) to > 1/14 of the allergens tested for. 
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3.7.  Questionnaires, structured interview and clinical examination 
3.7.1. Questionnaire used in the cross-sectional survey 
A questionnaire was earlier used in 1985 (43) (Appendix 1) and 1995 (125) (Appendix 2) to 
assess atopic disease among schoolchildren in northern Norway. The questions covered 
gender, age, family history of atopy, socio-economic conditions, passive smoke exposure and 
household animals. In 2008, we used the same questionnaire (Appendix 3), and added some 
questions about physical activity, diagnosis of asthma and asthma medication. The additional 
questions did not change the definition of diseases.  
 
3.7.2. Questionnaire and structured interview in the case-control study 
The children together with their parents/guardians completed a detailed questionnaire and a 
structured interview relating to asthma, AR, eczema, food allergy, urticaria, anaphylaxis, the 
use of medications, exposure to allergens, exposure to tobacco smoke, infections and other 
diseases during the first three years of life, diet and physical activity. Additional questions 
regarding demographic and socio-economic factors were answered and recorded. 
 
3.7.3. Clinical examination 
A clinical examination was performed including height and weight measurements and 
assessment of the skin, the upper airways, lungs and heart. ICS and short acting β-2 agonists 
were withheld for 12 hours prior to testing; inhaled long acting β-2 agonist for the last 48 
hours; leukotriene modifiers for the last 24 hours; and histamine in the last 5 days. No 
children were using oral steroids. 
 
3.8.  Clinical tests 
3.8.1. Allergic sensitisation 
Serum total IgE and sIgE: Blood samples were obtained using standard venepuncture using 
Vacutainer® tubes (Becton Dickinson, Plymouth, UK). Serum was collected and stored at  
-80°C until assayed. Total IgE and sIgE levels were analysed employing the IMMULITE® 
2000 (Siemens Healthcare Diagnostics Inc., Deerfield, IL, USA) using 3gAllergy® kits. The 
detection range for sIgE was ≥0.10-100 kU/L. The following were tested: sIgE to timothy, 
birch and mugwort pollens; dog dander, cat and rabbit epithelial dander; house dust mite 
Dermatophagoides pteronyssinus; moulds Alternaria tenius and Cladosporium herbarium 
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and German cockroach. Seroatopy was defined by a sIgE ≥0.35 kU/L to at least one of the 
listed allergens. Blood samples were requested for all children. 
 
Skin prick tests: SPTs were performed for the above listed allergens and egg white, milk, 
peanut and codfish with Soluprick® allergens (ALK Abello, Denmark). Histamine was used 
as positive control and saline as negative control. SPT was considered positive in the presence 
of a wheal diameter ≥3 mm larger than the negative control (126). During the initial study 
period, SPT was requested for all children. Thereafter, SPT was requested for children with 
asthma and/or allergy symptoms.  
 
3.8.2. Fractional exhaled nitric oxide (FENO) 
FENO was measured online by the single breath method with a chemiluminescence analyser, 
EcoMedics Exhalyzer® CLD 88sp with Denox 88 (Eco Medics AG, Duernten, Switzerland), 
(detection range 0.1-5000 ppb, accuracy ± 2%). The procedure was performed in accordance 
with published guidelines (127). The participants inhaled nitric oxide (NO) free air (< 5 parts 
per billion, ppb) to near total lung capacity to avoid contamination from ambient NO. The 
expiratory pressure was 5-20 mmHg to close the soft palate. Mean exhaled flow rate was 50 
mL/s ± 10% during the NO plateau. The manoeuvre was repeated until two exhalations 
agreed to within 5% coefficient of variation (CV) or three exhalations agreed to within 10% 
CV. The NO concentration, FENO, was defined as the mean of these values expressed in ppb. 
The analyser was calibrated daily using a standard NO calibration gas (Air Liquide 
Deutschland GmbH, Krefeld, Germany) and was corrected for ambient temperature and 
humidity. FENO was measured at baseline, prior to spirometry, and immediately after exercise 
(1 min) and 30 min later.  
 
3.8.3. Lung function and exercise test 
Spirometry 
Spirometry was performed in accordance with international guidelines (128) with an 
ambulant electronic spirometer, Spiro USB with Spida 5 software (Micro Medical, Rochester, 
UK). Forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and forced 
expiratory flow at 50% of FVC (FEF50) were reported using the reference values of Zapletal 




Standardised exercise test 
An exercise challenge test was performed by running for 6-8 min on a motor-driven treadmill 
(Woodway PPS Med, Woodway GmbH, Weil am Rhein, Germany) following the American 
Thoracic Society (ATS)/ European Respiratory Society (ERS) guidelines (131). The mean 
target heart rate during the last 4 min was 95% of maximum heart rate (calculated as 220 
minus age in years), though a minimum heart rate of 180 beats per minute, (85-88%) was 
accepted. In accordance with the study protocol, the exercise-induced bronchoconstriction 
(EIB) test was considered positive with a decrease in FEV1 ≥ 10% of baseline FEV1 measured 
at 3, 6, 10, 15 and 20 min after the exercise. Exclusion criteria were strenuous exercise within 
4 hours of testing and pre-exercise FEV1 lower than 75% of predicted value.  
 
3.9.  Annual pollen count and temperature measurements  
Pollen grains are tiny particles, which are released into the air and spread by the wind in order 
to pollinate plants of the same species. The pollen types of greatest significance for pollen 
allergy in Norway come from the tree species alder, hazel and birch and from all grass 
species, particularly timothy-grass and orchard grass. Other producers of pollen include 
wormwood, Salix (goat willow, osage orange and willow) and mugwort. Annual pollen 
counts are performed in twelve different meters placed in different locations in Norway (132). 
One of the meters is placed in the middle of our study area (Bodø). The meter counts the 
pollen (pollen grains/cbm air) from Alnus (alder), Coryllus (hazel), Salix, Betula (birch), 
Poaceae (grass) and Artemisa (mugwort) (133).  
 
The Norwegian Meteorological Institute (MET) produces forecast weather, monitors the 
climate and conducts research (134). MET publish global and national annual-mean surface 
air temperatures collected from monitoring stations throughout the world and in Norway. 
Annual-mean surface air temperatures are compared to the expected temperature or norm. 
The norm is defined as the 1961-1990 (30 years) mean. The annual-mean surface air 
temperature deviation from the norm is estimated and used to describe time trends.  
 
3.10 Statistical analyses 
Normally distributed values were presented as means and standard deviations (SD) or 95% 
confidence intervals (CIs). Categorical data were presented as percentages (percentage). All 
tests were two-sided using a significance level of 0.05. The distribution of FeNO values was 
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right skewed, and hence analyses were executed with natural log (ln) transformed data. The 
results were presented as back-transformed values and expressed as geometric means 
 
Paper I: The main outcome was differences in prevalence between the periods 1985-95 and 
1995-2008. The analyses were performed using chi-square statistics, and the differences in 
secular prevalence were quantified with odds ratios (OR). For values measured three times, 
chi-square tests for trend (linear-by-linear associations) were calculated.  
 
Paper II: The validity of the questionnaire was determined by agreement between 
questionnaire responses and clinical assessments. Agreement was measured as sensitivity and 
specificity. Corrected estimates for the prevalence of asthma ever and current asthma were 
calculated as the sum of the positive predictive values (PPV) for both positive and negative 
questionnaire replies to asthma, weighted by their relative frequencies. Agreement between 
EIB and clinical assessment was assessed using post-test odds and the probability for a 
positive EIB tests. The test-retest reliability of the questionnaire was assessed using Cohen’s 
kappa. Corrected inter-group comparisons were analysed with Pearson’s chi-square test for 
categorical data and independent t- test for continuous data.  
 
Paper III: To assess possible differences comparing demographical data between groups we 
used Pearson`s chi square-test for categorical data and independent t-test for continuous data. 
Since the survey design in paper III was a matched case-control design, the other analysis 
used had to take the matching between cases and controls into account and adjust for paired 
data. When comparing the matched case-control groups, McNemar’s chi square-test was used 
for categorical (binary) variables (e.g. LRTI shown in table 2) and paired-sample t-test for 
continuous variables, both methods comparing cases and controls without adjusting for any 
confounders. The use of McNemar`s chi-squared test is valid provided that the total number 
of discordant pairs is at least 10.		
	
Table 2. McNemar’s test applied for the variable lower respiratory tract infections (LRTIs). 
  Current asthmatic   
  LRTIs yes LRTIs no Total 
LRTIs yes 5 9 14 Non - asthmatic 
LRTIs no 59 80 139 
 Total 64 89 153 
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The results from paired chi-square test based on the discordant pairs in table X can be used to 
calculate chi-square to establish the p-value by the formula: χ2 = (r-s)2/r+s, d.f = 1. The odds 
ratio = ratio of discordant pairs. For LRTIs (table 2) OR = 59/9 = 6.56. 
 
To compare cases and controls in an adjusted model, we needed to use a regression model. A 
standard logistic regression model would assume that all observations were independent. 
However, with paired data the observations within each pair were interdependent. This 
assumption had to be adjusted in the model by using conditional logistic regression. 
Conditional logistic regression is a variant of logistic regression in which cases are only 
compared to the controls in the same pair (19). This method is implemented in most statistical 
packages but not in SPSS. However, one can still perform conditional logistic regression in 
SPSS using stratified Cox proportional hazards model to estimate odds ratios. Cox requires a 
specified observation time for each individual, which was achieved by creating a constant 
time link i.e. had equal value for each individual in the data set. A stratified Cox model where 
the status variable was current asthma (yes/no), the observation time variable had equal value 
(time = 1) for each individual and a strata variable indicating each pair (pair number) gave 
identical regression coefficients, and thus also OR, as with conditional logistic regression.  
  
Building the model, we first assessed whether or not an independent variable was a potential 
confounder, which could be difficult to determinate. We considered the biological relations 
between the variables and compared the regression coefficient before and after adjusting for 
possible confounders. If the regression coefficient changed by more than 10%, we most likely 
had a confounding variable. Two variables in 2008 were considered as confounders, namely 
AR and hospitalization. Thus, they were included in the final model. Likewise, atopy in the 
family was considered as a confounder in 1985, and was therefore included in the model. 	
 
Of potential risk factors, the most relevant relationships were assessed in unadjusted analysis 
and factors with an unadjusted p-value < 0.25 were included in the model. Variables 
considered as mediators or colliders were not included in the model. Deciding whether or not 
the variables were mediators or colliders, was done by consideration in addition to statistical 
analysis. Working with the multivariable model, we identified ‘regular use of asthma 
medication during the first three years of life’ as a collider interrupting the model since it is 
strongly correlated to current asthma (reverse causality). The same situation applied to the 
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variable ‘asthma symptoms during the first three years of life’. Variables in the multivariable 
model were excluded in a stepwise fashion to increase the strength of the model regardless of 
significance. The final model included statistically significant covariates as well as 
confounders whether or not formally statistically significant at the 5% level.  
 
All analyses were made using Graph Pad Prism version 5 (Graphical Software, San Diego, 
CA, USA) and Statistical Package for Social Science (SPSS) software version 19.0 and 







Figure 5. A flow chart for study subjects in ‘Asthma and Allergy among schoolchildren in 
Nordland County.  
aSubjects categorized as non-asthmatic after clinical assessment. 
bSubjects misclassified as non-asthmatics, new cases of asthma. 
 
4.1.  Prevalence of asthma, AR and eczema 1985-2008  
Of the 6505 pupils invited to participate, 4150 (63.8%) answered the questionnaire (figure 5) 
and were enrolled in the study (49.1% boys). Demographic data from the three questionnaire 
based surveys performed in 1985, 1995 and 2008 are presented in table 3. 
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Table 3. Demographic data of the study groups from the questionnaire based surveys in 
1985, 1995 and 2008 in Nordland County.  
 Surveys  
  
1985 % 1995 % 2008 % 
p for 
trend 
Number of children invited 
to participate 
5134 100 5121 100 6505 100 
 
Responders 4870 94.9 4456 87.0 4150 63.8  
Boys (n) 2505 51.4 2248 50.4 2036 49.1 0.025 
Girls (n) 2365 48.6 2208 49.6 2114 50.9 0.025 
Mean age (years) 10.3  10.8  10.8   
Atopic diseases among 
family members  
2387 49.0 2813 63.1 2878 69.9 < 0.001 
Parental history of asthma 363 7.7 519 11.6 690 16.8 < 0.001 
Parental history of allergy 699 14.8 980 22.0 1294 31.4 < 0.001 
The data are presented in exact numbers and in percentages (%). N varies due to 
missing data. 
        








Figure 6. The prevalence (%) of asthma ever, AR ever and eczema ever in schoolchildren 
from the three questionnaire-based surveys in Nordland, 1985–2008.  
 
The main findings were an increasing prevalence of asthma ever (p for trend <0.001) and AR 
ever (p for trend <0.001), while the prevalence of eczema ever, after an increase between 
1985 and 1995, remained unchanged in the last period (figure 6).  
 
The results demonstrated a gender difference (figure 7). The prevalence of asthma ever and 
AR ever were significantly higher among boys compared to girls in all three surveys, while 
the prevalence of eczema ever was approximately similar between girls and boys in 1985 and 































Figure 7. The prevalence (%) of asthma ever, AR ever and eczema ever from the three 
questionnaire-based surveys in Nordland, 1985–2008, divided by gender.  
 
The prevalence of current disease doubled and trebled between 1995 and 2008 for all three 

































AR ever boys 
AR ever girls 
Eczema ever boys 
Eczema ever girls 
Asthma ever boys 
Asthma ever girls 
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Table 4. The prevalence of current asthma, allergic rhinoconjunctivitis and 
eczema in children aged 7-14 years from the 1995 and 2008 questionnaire-  
based surveys in Nordland County.  
 Prevalence (%)   
 Surveys 2008/1995 
  1995 2008 OR 95 % CI 
All     
Current asthma 4.8 9.9 2.21 1.86-2.62 
Current rhinoconjunctivitis 6.7 21.5 3.83 3.33-4.40 
Current eczema 6.4 13.5 2.27 1.96-2.64 
Boys     
Current asthma 5.6 12.0 2.29 1.83-2.87 
Current rhinoconjunctivitis 7.5 24.4 3.80 2.15-4.58 
Current eczema 6.2 12.3 2.11 1.70-2.62 
Girls     
Current asthma 3.9 8.0 2.13 1.63-2.78 
Current rhinoconjunctivitis 5.8 18.7 3.70 3.01-4.56 
Current eczema 6.6 14.6 2.43 1.97-2.99 
The difference in prevalence between 2008/1995 is quantified with odds ratio  
(OR). Corresponding 95 % confidence intervals (95% CI) are presented.      
     
Adapted from Hansen et al. Acta Paediatr 2012; 102:47-52.  
 
The proportion of children reporting at least one disease (asthma, AR or eczema) increased 
from 26.2% in 1985 to 43.3% in 2008 (p for trend <0.001). The proportion of children with 
all three diseases and the proportion of children with both asthma and eczema increased 
during the study period, while the proportion of children reporting the combination of asthma 
and AR or AR and eczema after an increase in the first period stayed unchanged in the last 
period. An increasing proportion of the responders reported atopic disease in the family (p for 
trend < 0.001) (table 3).  
 
4.2.  Validation of the survey questionnaire  
Of the 1144 pupils invited, 801 children accepted to participate in the case-control study. This 
represents a participation rate of 70%. In the case-control study, 373 children reported 
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‘asthma ever’ (figure 5). After the clinical assessment, 64 of the designated 373 asthmatic 
children did not meet the asthma definition criteria (i.e. false positives). Of the 428 apparent 
non-asthmatic children, 14 met the asthma definition criteria after the clinical assessment (i.e. 
false negatives). After reclassification, the group of asthmatic included 323 children (63.2% 
boys) and the non-asthmatic group included 478 children (figure 5). Asthmatic children had 
higher mean body mass index (BMI) and suffered more frequently from eczema, AR and food 
allergy than non-asthmatic children (table 5), otherwise the two groups were similar regarding 
demographic features. 
 
Table 5. Demographic data of asthmatic and non-asthmatic children in the case-control  
study from "Asthma and allergic diseases among schoolchildren in Nordland" 
  Asthmatic Non-asthmatic P - value 
  n = 323 n = 478   
Boys (%) 204 (63.2) 286 (59.8) 0.343 
Mean age (years) 12.4 12.6 0.185 
Mean Body mass index (BMI) 20.3 19.6 0.014 
Mean birth weight (grams) 3467 3537 0.150 
Mean gestation age (weeks) 39.3 39.5 0.222 
Mean fathers’ years in school 13.2 13.5 0.103 
Mean mothers’ years in school  14.0 14.1 0.529 
Passive smoke exposition (%) 116 (35.9) 143 (29.9) 0.075 
Comorbidity    
Eczema (%) 157 (48.6) 153 (32.0) < 0.001 
Allergic rhinoconjunctivitis (%) 156 (48.3) 127 (26.6) < 0.001 
Food allergy (%) 49 (15.2) 32 (6.7) 0.001 
Urticaria (%) 56 (17.3) 93 (19.5) 0.441 
The data are presented in exact numbers and in percentages (%).  
    
Adapted from Hansen et al. J Asthma 2014; 52:3, 262-267 
 
Compared to clinical assessment, the survey questionnaire had a sensitivity of 0.96 and a 
specificity of 0.87. The overall agreement (kappa) was 0.80 (standard error (SE) 0.02). 
Assuming that the clinical assessment represents a true diagnosis of asthma (‘gold standard’), 
the estimated prevalence of asthma ever in the 2008 survey was adjusted from 17.6% to 
16.9% (SE 0.006, 95% CI: 15.8-18.0). Similarly, the prevalence of current asthma was 
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adjusted from 9.9% to 10.8% (SE 0.005, 95%CI: 9.8-11.8). The most sensitive and specific 
questions identifying asthmatic children by the questionnaire were questions asking about 
diagnosis (‘Has the child ever had asthma?’) rather than those covering asthma symptoms 
such as wheeze, shortness of breath and/or cough (data not presented).  
 
Asthmatic children were often sensitised to allergens, had higher FENO values and had more 
often a positive EIB test than non-asthmatics. However, spirometric values were not 
significantly different between the groups (table 6). A positive exercise test yielded a 
sensitivity of 0.12 and a specificity of 0.92 relative to the clinical assessment. The post-test 
odds and the post-test probability were 0.33 and 0.25, respectively. 
  
Table 6. The test results for asthmatic and non-asthmatic children in the case-control 
study from ‘Asthma and allergic diseases among schoolchildren in Nordland’. 
  Asthmatic Non-asthmatic p - value 
  n = 323 n = 478   
Positive skin prick test (%) 162/216 (75.0) 118/169 (69.8) 0.258 
Positive IgE, Inhalation  162/162 118/118  
Positive IgE, Food 28/162 11/118  
One or more positive sIgE (%) 179/257 (69.6) 234/385 (60.8) 0.022 
Positive specific IgE, Inhalation 172/179 213/234  
Positive specific IgE, Food 82/179 81/234  
Allergic sensitisation (%) 218 (67.5) 259 (54.2) 0.000 
Mean baseline FeNO (95%CI) 14.74 10.75 0.000 
Mean baseline lung function     
FEV1 (95% CI) 2.59 (2.51-2.67) 2.63 (2.56-2.69) 0.492 
FVC (95% CI) 3.00 (2.90-3.09) 3.06 (2.98-3.14) 0.273 
FEV1% (95% CI) 86.1 (85.4-86.8) 85.8 (85.3-86.4) 0.547 
FEF50 (95%CI) 3.13 (3.01-3.24) 3.15 (3.06-3.24) 0.695 
predFEV1 (95%CI) 2.73 (2.65-2.80) 2.67 (2.61-2.73) 0.295 
predFVC (95%CI) 3.24 (3.15-3.33) 3.16 (3.09-3.23) 0.244 
pred FEF50 (95%CI) 3.85 (3.76-3.94) 3.80 (3.72-3.88) 0.486 
Positive exercise test (% of total) 57/315 (18.1) 26/466 (5.6) 0.000 
The numbers are presented as exact numbers and percentages or means  
    
Misclassified children who were transferred from the asthma group to the non-asthma group 
(false positive) after the clinical assessment, 21/64 (32.8%) answered affirmatively to 
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Question 1 in the original questionnaire and 52/64 (83.9%) answered affirmatively to 
Question 2. The interview revealed that 39.1% of the 64 children had experienced respiratory 
symptoms, but not asthma during the first three years of life. In 22/25 (88.0%) of these 
children the episodes of symptoms were associated with fever, colds or other airway 
infections. In the group of misclassified children that changed groups from non-asthmatic to 
asthmatic (n=14) after the clinical assessment (false negative), eight children represented new 
asthma cases. 
 
4.3.  Risk factors for the  development of asthma  
Demographic data from the study populations in 1985 (n = 207) and 2008 (n = 801) displayed 
a male dominance of 65.7 % and 61.2 %, respectively. Mean ages were 11.4 years in 1985 
and 12.5 years in 2008. Atopic diseases in the family was significantly different between 
cases and controls in both studies, otherwise the subgroups were similar in terms of 
demographic data and clinical characteristics. Comparing demographic and clinical data 
between sexes revealed a significant difference in the prevalence of AR in 2008 (boys 38.4% 
and girls 30.5%; p = 0.024), while there were no differences between the sexes in 1985.  
 
4.3.1. The 1985 study 
Of the 105 cases, 62 fulfilled the criteria for current asthma. Comparing these to their 
respective controls revealed associations between some variables and the outcome current 
asthma. The final model revealed significant differences between cases and their matched 
controls in adjusted OR (95% CI) (P-value): Repeated LRTIs AOR 52.11 (95% CI 4.62-
587.97) (p = 0.000), atopy in the family AOR 13.20 (95% CI 1.60-108.63) (p = 0.016), 
urticaria ever in the child AOR 11.27 (95% CI 1.01-125.33) (p = 0.049), and duration of 
breastfeeding AOR 1.35 (95% CI 1.02-1.80) (p= 0.039).  
 
4.3.2. The 2008 study 
Of the 323 cases, 153 fulfilled the criteria for current asthma (figure 5). Comparing them to 
their controls revealed associations between a number of variables and the outcome current 
asthma. The final model included a total of seven variables: duration of breastfeeding, mean 
number of hours watching television and/or data during weekdays, AR, food allergy, LRTIs 
during the first three years of life, hospitalisation caused by LRTIs and allergic sensitisation. 
The explained variance for current asthma by all seven variables was 61% with the most 
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important risk factors; food allergy AOR 7.06 (95% CI 1.61-31.07) (p = 0.010), LRTIs during 
the first 3 years of life AOR 5.80 (95% CI 1.96-17.21) (p = 0.002), and hospitalisation caused 
by LRTIs OR 4.60 (95% CI 1.01-20.96) (p = 0.049). The only factor associated with a 
reduced risk for current asthma was length of breastfeeding OR 0.93 (95% CI 0.87-0.99) (p = 
0.025).  
 
Analysing the present data by gender displayed some differences from the data for all 
children. For boys food allergy AOR 18.32 (95% CI 1.54-217.74), LRTIs during the first 3 
years of life AOR 8.87 (95% CI 2.07-37.96) and AR AOR 4.12 (95% CI 1.10-15.4) were 
significantly different between cases and controls. For girls LRTIs during the first 3 years of 
life AOR 7.70 (95% 1.18-50.36), duration of breastfeeding AOR 0.89 (95% 0.79-0.99) and 
time spent in front of television or data AOR 1.65 (95% CI 1.11-2.45) were significantly 
different between the cases and controls.  
 
4.3.3. Changes in the climate and pollen count 
During the period 1985-2008, the average temperature raised 0.5°C in northern Norway 
compared to the norm (figure 8). In the same period, the global average temperature increased 




Figure 8. Deviation in annual-mean temperature from the expected (norm) temperatures in 
northern Norway in the period 1985-2011.  
The bars show the annual-mean deviation from the norm, while the line shows the time trend. 
 




Figure 9. Deviation i annual-mean temperature from the expected (norm) temperatures 
global in the period 1985-2011. 
The bars show the annual-mean deviation from the norm, while the line shows the time trend. 
 
Source reference: The Norwegian Meteorological Institute 
 
The total pollen count measured in Nordland (Bodø) during the period 1985-2011, displayed 
an increasing temporal trend (figure 10). In particular, 2008 when the cross-sectional survey 







Figure 10. Total pollen production (pollen grains/cbm air) in Nordland county during the 
period 1984-2011 (133). The total pollen production includes pollen from Salix, Betula 
(birch) and Poaceae (grass). The dotted line marks the temporal trend.  
 






































5.1.  Prevalence of asthma, AR and eczema 1985-2008  
We demonstrated an increasing prevalence of asthma ever and AR ever, while the prevalence 
of eczema ever, after an increase between 1985 and 1995, stayed unchanged in the last period.  
The prevalence rates found in 2008 are similar to those reported from the ECA study in Oslo 
(52), but somewhat higher compared to results in the OLIN study in northern Sweden (103, 
135). In contrast to prevalence studies in comparable populations (34, 49, 52, 136), we found 
a substantial increase in the proportion of children reporting current diseases in the last 
period. 
 
Assessing time trends in asthma prevalence, a continuing increase has been revealed in some 
countries even though the prevalence of asthma has declined in other countries (2). The main 
challenges studying asthma prevalence are the absence of a standardised definition of asthma 
and the lack of a gold-standard diagnostic test (25). These challenges make comparison 
between different studies difficult and may influence the interpretation of the results.  
 
Asthma, AR and eczema are common and closely related (52, 70). Even if the 
interrelationships are not well understood, studies have suggested a shared causal mechanism 
(72). The proportion of children suffering from asthma, AR and eczema increased and the 
proportion of children with none of these diseases decreased significantly in the study 
population from 1985 to 2008. The combination of asthma and eczema increased during the 
entire period while the combinations of asthma/AR and AR/eczema increased in the period 
1985-95 and then levelled off in 2008. This pattern is in line with the findings in a report from 
the ISAAC III study (137). The extensive overlap between these atopic diseases is important 
to acknowledge since the risk of asthma and other allergic diseases might increase with an 
increasing number of allergic manifestations in infancy (138). A recent study from the 
MeDALL showed that at the population level, childhood asthma, rhinitis and eczema are 
more accurately classified together as an allergic comorbidity cluster, rather than three 
independent diseases (139). Taken together, these findings imply that diagnosing and treating 
comorbid rhinitis and eczema is important as it has consequences for treatment and 




5.2.  Validation of the questionnaire from the cross-sectional survey  
Validation of epidemiological tools is important in order to achieve knowledge about their 
usefulness. When validating the questionnaire from the cross-sectional surveys against 
clinical assessment, we found very good agreement between the questionnaire-based 
diagnosis of asthma and the clinical assessment by a doctor. For a questionnaire to be a useful 
research tool, the responses must be repeatable (minimum measurement error). The test-retest 
reliability of asthma definition by questionnaire can be judged substantial (140), especially 
considering the time interval between the cross-sectional survey and the case-control study. 
Thus, the questionnaire is a useful epidemiological tool.  
 
The diagnosis of asthma is problematic as episodic symptoms and exacerbations are essential 
components of the disease. This makes the use of clinical testing as a diagnostic and 
epidemiological tool challenging. In agreement with other studies (24, 31,141), the intensive 
examinations performed in the case-control study yielded little additional information 
compared to clinical assessment. The EIB test increased the post-test probability only to a 
minor degree, whilst spirometric values and SPT results did not differ between asthmatic and 
non-asthmatics. However, baseline FeNO was significantly higher in asthmatic than in non-
asthmatic children, which is in line with findings from the ECA study in Oslo (142). The 
difference in baseline FeNO is probably due to the higher proportion of asthmatic children 
suffering from comorbid AR, as showed in an earlier publication from the study ‘Asthma and 
allergy among schoolchildren in Nordland’ (143).  
 
Investigating the misclassifications and over-diagnoses in the case-control study, we found 
that most of them were due to parents response to Question 2 in the 2008 survey. Question 2 
covered several symptoms including the cardinal symptom of asthma, wheeze, as opposed to 
the corresponding question in ISAAC covering only wheeze (32). This represents a difference 
in the definition of asthma ever making directly comparison between the results from the 
present study and the ISAAC studies (49) difficult. Thus, a crucial consideration is which 
approach is more appropriate for assessment of the prevalence of asthma. A Danish study 
from 2012 found that doctor-diagnosed ‘wheeze’ is not a prerequisite for the diagnosis of 
asthma either and proposed focus on symptom burden in clinical practice to reduce the risk of 
misclassification of asthma in young children (144). Other symptoms as persistent cough, has 
been shown to be as closely related to asthma as wheeze (16). On the other hand, several 
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symptoms included in one question could lead to misinterpretations and insecurity towards 
differential diagnosis of asthma. The clinical assessment revealed that parents responding 
positive to Question 2 in the 2008 survey misinterpreted their child’s symptoms associated 
with respiratory infections in early life as asthma. This finding is in line with results from an 
international study among preschool children (145). In our opinion, the false positive children 
in the study may represent ‘transient infantile wheeze’ (11).  
 
Questions covering diagnosis rather than symptoms in the 2008 survey provided a better 
prediction of asthma prevalence, even though diagnosis itself does not constitute an 
‘objective’ record. Even if diagnostic customs change over time, questions relating to 
diagnosis may be more useful than symptom-based questions in some instances. Hence, in 
future studies regarding the prevalence of asthma, we must critically consider the need for 
revising Question 2 or excluding it from the questionnaire. 
 
In the 2008 case-control study, no cases suffered from moderate or severe asthma. Similarly, 
the ISAAC studies have revealed that the overall increase in asthma prevalence reflects 
milder disease (50). This may represent a real change in diagnostic habits in the period of 
1985-2008. In addition, physicians seems more prone to include children with milder 
symptoms who previously would not have had an asthma diagnosis (2). One likely cause for 
the observed change is the introduction of ICS treatment, which took place in the early 1980s 
(146).	There is no doubt that the introduction of inhaled steroid therapy revolutionised the 
management of patients with chronic asthma, including the milder cases that previously did 
not have a real treatment offer.  
 
5.3.  Possible risk factors for current asthma 
One or repeated LRTIs during the first three years of life, reported by the parents, was the 
strongest association for current asthma in both 1985 and 2008, together with severe LRTIs in 
the 2008 study. Others studies showing that early severe LRTIs are associated with up to a 
four-fold risk of subsequent wheeze during early school years (147) supported these results. 
In a Norwegian study, the risk of development of asthma and lung function alterations after 
bronchiolitis in early life was found to be influenced by gender and type of virus involved 
(148). Recent research from the COPSAC study revealed that otherwise healthy children 
experienced a median of 10 episodes of respiratory tract infections (one episode per child for 
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LRTIs) during the first 3 years of life (149). Findings in this Danish study suggest that host 
factors are the major determinants of infection susceptibility in early childhood (149). To 
some extent our findings contradict the assumption of the hygiene hypothesis stating that 
more infections early in life prevent the development of atopic diseases due to the diversity of 
the ‘microbial burden’ (76). Whether the infection susceptibility in early childhood has 
changed during recent decades leading to an increase in the incidence of respiratory tract 
infections, is unknown. 
 
AR and food allergy were risk factors for current asthma in the 2008 study. Both diseases 
frequently coexist with asthma (70, 150). Food allergy and atopic dermatitis commonly 
coexist at the beginning of the ‘atopic march’. Questions have been asked as to whether the 
observed association between asthma and food allergy is related to co-manifestation or if it is 
a consequence of food allergy itself (60). Although gender difference in asthma prevalence is 
well documented, gender-dependent risk factors for asthma have not been fully elucidated 
(151). Stratification by sex in the 2008 study displayed sex-dependent risk factors: 
comorbidity of AR and food allergies was significantly different between cases and controls 
in boys. Although these associations were strong, this could be the result of a higher 
prevalence of AR in boys in the original study groups and twice as many matched pair of 
boys than girls. Our findings are in line with results from the ECA study (152) and support 
the hypothesis that asthma and combinations of allergic comorbidities may represent a 
gender-related phenotype.  
 
The greatest distinctions between the results in 1985 and 2008 were the association of 
breastfeeding to current asthma and the significance of atopy in the family. In the case of 
breastfeeding, we believe this may be an example of inverse causation: debut of asthma 
symptoms prolong the duration of breast-feeding because of the general belief in its protective 
effect. Such inverse causation could be misinterpreted, drawing the conclusion that longer 
breast-feeding leads to asthma, when in fact it is the reverse (107). Breast-feeding presumably 
has a protective effect against viral respiratory infections (153). Since LRTIs show a strong 
association towards current asthma, the association with breastfeeding in the 2008 study 
might be brought about by its protective effect against LRTIs (154).  
 
In the 1985 study, current asthma was associated with family atopy. Unlike other studies (58, 
80), we were unable to find an association between current and parental asthma, AR and/or 
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eczema in the 2008 survey. In the period 1985-2008, there was a substantial increase (up to 70 
%) in the prevalence of atopic diseases in the family. This high prevalence regardless of 
asthma status in the child, may partly explain the difference.  
 
Compared to the global annual-mean temperature, the annual-mean temperature in northern 
Norway has increased more than twice during the study period. Although the underlying 
causes of the rising trend of allergic disease are not clear, links have been made to various 
climatic factors as temperature, and their impact on the production and distribution of pollen 
and mould (155). Others have shown that warmer temperatures positively correlate with 
physician-diagnosed allergic rhinitis (156). Temperature is an important variable for spring 
and early summer pollination of allergenic trees and grasses (155). The yearly pollen count in 
the study area had an upward trend, with exceptionally high counts during the years of 2008-
2010, compared to previous years. These raised counts suggest that the increased annual-
mean temperature in northern Norway may have led to a rise in pollen production and 
furthermore increased the prevalence of AR. AR was identified as a risk factor for current 
asthma in 2008. Hence, AR might have contributed to the increased asthma prevalence in the 
in the period 1985-2008. In addition, other local environmental factors might have 
contributed to the increased asthma prevalence. During winter, children living in a cold and 
coastal subarctic climate are expected to spend more time indoors compared to children living 
in a warmer climate. Others have proposed this as having a negative effect on the 
development of asthma and eczema symptoms (111). 
 
5.4.  Methodological considerations  
When evaluating the outcome in epidemiological research, it is custom to consider random 
and systematic error that may affect the internal validity of the study. Random error reflects a 
problem of precision in assessing a relationship between exposure and disease and can be 
reduced by increasing the sample size (157). Systematic error (bias) is a systematic deviation 
of a study's result from a true value and can be divided in selection and information bias and 
confounding (21). Selection bias concerns the process of identifying study subjects, while 
information bias occurs when any information used in a study either is measured or recorded 
inaccurately (158). Possible biases in epidemiological studies of asthma have many sources, 
including but not restricted to: sampling method and timeframe, response rates, recall bias, 
awareness of asthma, diagnostic habits, the nature of the questions asked and definition 
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criteria of asthma. In addition, observer bias and seasonal bias may influence results 
(159,160). Confounding occur when a variable is related with the exposure and also 
influences the disease outcome which may lead to incorrect conclusions about the effect of 
the exposure of interest on the outcome (161). In the following sections, the most important 
strengths and limitations of ‘Asthma and allergy among schoolchildren in Nordland County’ 
are discussed in relation to study design, bias and confounding. 
 
5.4.1. The cross-sectional survey (paper I) 
The original study cohorts in 1985, 1995 and 2008 were large and consisted of unselected 
children in Nordland county randomly selected, making the study group a representative 
fraction of the general child population. We used identical study design and the same 
questions defining disease in three repeated cross-sectional surveys during three decades in 
the same population, forming a basis for valid time trends for self-reported asthma, AR and 
eczema. The best evidence of changes in prevalence comes from repeated studies using the 
same questionnaires or investigations in the same population at sufficient time intervals (2). 
The cross-sectional study design was chosen due to its time- and cost-efficient way to assess 
the prevalence and because it is as close a proxy as it is possible to attain for the preferred 
method of longitudinal data. 
 
Selection bias is best avoided by achieving a high response rate. Even though a high 
participation rate is preferable, most empirical work suggests that lower participation rates are 
not likely to have a substantial influence on the measures of interest (162). Different factors 
affect participation in epidemiological studies: methods of recruitment, family and medical 
history, disease status, questionnaire structure and method and number of contact (20). The 
response rate in the three surveys decreased during time and the rate in the 2008 survey was 
lower than desirable. Due to ethical considerations, in 2008 we were not allowed to give 
personal reminders to the participants in contrast to the earlier studies. We believe this partly 
explains the lower response rate in 2008. In addition, decreasing participation rates have 
become more common in recent decades. This is most likely due to the increasing number of 
studies and research projects offered to the public. Thus, refusals to participate have increased 
(163).  
 
The lower response rate in 2008 may represent a selection bias if there were differences in 
characteristics between those who did respond and those who declined participation. Such a 
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difference may have affected the estimates of prevalence (21). Unfortunately, it was not 
possible to perform any analysis of the non-responders in the 2008 survey to investigate if 
they differed from the study subjects. Analyses of non-responders have been performed in 
other studies with contrasting results. Some have demonstrated differences in socio-economic 
conditions affecting outcome (164), while others have concluded that differences in 
sociodemographic background between responders and non-responders did not influence 
prevalence estimate noteworthy (165, 166). In a large postal survey performed in Sweden 
(167) non-responders did not differ significantly in the prevalence of airway diseases or 
symptoms compared with responders. Either way, study subjects willing to participate in 
unselected cohort studies are generally more likely to have a history or risk of asthma or 
related diseases (16). In addition, parents suffering from atopy are thought to be more aware 
of symptoms and diseases in their children (168).Considering the increase in prevalence of 
atopic diseases in the family from 1985-2008, an overrepresentation of children with a 
positive family history of atopic diseases in the present study were likely. This 
overrepresentation might entail a selection bias affecting the prevalence estimates and making 
the result difficult to generalise to other populations.  
 
Repeated cross-sectional written questionnaires based surveys lack objective data. Thus, 
perception of increased prevalence should be treated with caution due to changes in 
awareness and diagnostic habits. Asthma and allergic diseases have been given considerable 
public health and media attention especially in Western societies in the same period as the 
‘asthma epidemic’ has arisen. The impact of increased general awareness has been proposed 
to explain some of the increasing trend in the prevalence of asthma (2, 57). The increased 
general awareness together with changed diagnostic habits represents information bias and 
may have influenced the time trends in our study population.  
 
When calculating the estimated time trends of asthma, AR and eczema, we did not evaluate or 
adjust potentially confounding factors. In order of making the analysis more reliable, we 
could have included potentially confounding factors as gender and family atopy, in the time 
trend analysis.  
 
5.4.2. The case-control study (paper II and III) 
A major advantage of the case-control study was the substantial clinical characterisation of 
the participating children together with detailed questionnaires and structured interviews. Two 
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paediatric doctors conducted all the interviews, clinical examination and clinical testing using 
the same medical instruments to secure standardised measurement conditions. The procedures 
were performed in accordance with validated published guidelines (127, 128, 131). Hence, the 
clinical assessment can be regarded as consistently reported and reliable, which strengthens 
the statistical power and the internal validity of the results. 
	
Confirmative parental reports on asthma (question 1 and/or 2) defined the status of asthma 
ever for the entire cross-sectional survey (paper I). The two paediatric doctors determined the 
asthma status in the case-control study during the clinical assessment (paper II). After the 
asthma status and the severity of disease were determined, clinical testing was conducted. It 
was executed in this way for two reasons: a) we did not want to let the test results influence 
the decision about asthma status and, b) we wanted to investigate if clinical tests added extra 
information to clinical assessment. However, there are two obvious limitations with this 
approach. The first is the lack of probability weighting to correctly estimate how many true 
asthma cases and true controls one would have in the total population from the cross-sectional 
survey and how many of them were test positive and test negative. Without probability 
weighting, one needed to be sure that the original randomisation process for choosing test 
positives and test negatives really fulfilled the criteria for random sampling. If not, it may 
violate independence between disease status and exposure status in the case-control study and 
influence the sensitivity and specificity measures. We believe that the randomisation process 
was good enough to prevent a massive influence on the validation measurements, even if 
lower response rate than preferred likely entailed a selection bias (as discussed in section 
5.4.1). This assumption is strengthened by the results from another Norwegian study, which 
demonstrated similar sensitivity (0.96) and specificity (0.88) when they validated the current 
questionnaire (45).  
 
A second limitation to the approach used is that the reviewers were not blinded to the 
previous parental reported asthma status in the child. Bias can occur if reviewers are aware of 
the study hypothesis and subconsciously or consciously gather data selectively (21).	Ideally, 
the reviewers should have been blinded to avoid misclassifications based on prejudice or 
beliefs. Unfortunately, this was not possible within the organization of the study due to 
limited resources. This is one of the unfortunate disadvantages when performing extensive 
research outside university premises in small research environments. However, the reviewers 
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had no knowledge about the specific answers to the individual questions in the cross-sectional 
survey. Therefore, we believe that this has only influenced the results in a minor degree. 
 
Misclassification of outcomes caused by inter-observer variation is a risk in classical 
epidemiologic studies based on information from questionnaires. Misclassification is a type of 
information bias and may be defined as the assignment of a wrong value for a given piece of 
information (158). This is especially important when analysing diseases, such as asthma, in 
which the clinical presentation is essential to the diagnosis (16). The present study combined 
the best qualities in combining questionnaires and testing, namely, by first performing a 
questionnaire survey and subsequently conducting more intensive examinations on a large 
subsample of children. This led to a reduced risk of further misclassification in the case-
control survey. However, it is important to remember that sensitivity and specificity of  
‘diagnostic tools’ must be interpreted in the light of the definition of asthma that was used and 
the population that was studied (9). Since both symptomatic and non-symptomatic study 
subjects were examined, it was possible to estimate the extent of misclassification in the 
questionnaire survey. We used current asthma (symptoms and/or use of medication the last 12 
months) as the definition of cases when comparing asthmatic and non-asthmatic children 
(paper III), since questions about current disease are more reliable than questions about 
symptoms ever due to less recall bias.  
 
A major challenge in retrospective studies is recall bias, a second type of information bias. 
Recall bias occurs when study subjects report inaccurate information. In case-control studies, 
cases are more likely to recall previous risk factors than controls. Recall bias affecting only 
one of the study groups may produce a spurious association between the exposure and the 
outcome resulting in higher prevalence and positively biased odds ratio estimates. 
Inconsistency concerning information on children’s chronic health conditions (asthma) based 
on medical record data and parents-reports has been reported (169, 170). On the other hand, 
self-reported symptom history seems to represent the necessary basis for defining asthma in 
epidemiological studies (31, 57). Reliability in the present study could have been checked by 
resubmitting the questionnaire used in the cross-sectional survey to a subgroup of 
participants. Unfortunately, we did not preform such test of reliability. However, during the 
structured interview in the case-control study some of the questions were repeated as part of 
the assessment of asthma, AR and eczema status. In addition, the proportion of children 
reporting use of asthma medication ever and last year in the cross-sectional survey was 
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similar to the prevalence of asthma ever and current asthma, which strengthen the results.  
 
Another limitation inherent in asthma questionnaires is that questions covering diagnosis and 
clinical assessment may not be truly independent of each other. As a diagnosis is not merely 
an objective record, it could include an intervention that may affect parental perception. This 
problem with ‘circularity’ can make it difficult to evaluate whether parents are just recalling 
previous outcomes when answering questions concerning diagnoses. Thus, caution is needed 
when making definitive statements. 
 
Case-control studies include the ability to control for multiple confounders and the ability to 
assess multiple exposures of interest. Confounding in any direction is important to the degree 
that it results in erroneous conclusions about the effect of the exposure on the outcome (161). 
We performed a matched case-control study to minimize for potential confounders in the 
exposure-outcome relationship and to increase the statistical efficiency (171). One problem 
with the matched analysis is the loss of all the information from the concordant pairs. Thus, 
unless the matching factors are strongly associated with both outcome and exposure, the 
gained efficiency may not be worth the extra analytic complexity (19). Studying asthma, we 
considered the matching to be worth the effort since sex and age are strongly associated with 
asthma and several of the exposures variables. It is essential to note that since matching was 
used in the design, the analysis had to take this into account.  
 
Even if confounding bye age and gender were addressed through the matching, we had to 
consider confounding from the other measured variables. The variables atopy in the family in 
1985 and AR and hospitalization in 2008 were considered as confounders. Thus, we needed 
to minimize the confounding by including the variables in their respective models. Even if 
confounding was addressed through the study design and analysis, still confounding by 
chance or unmeasured factors may have remained. The likelihood of strong baseline 
confounding occurring by chance decreases as he study size increases (161). The size of 
original study cohorts were large as was the subsample examined in the case-control in 2008. 
We believe this minimalized unmeasured confounding and confounding by chance. 
 
In a case-control design, both exposures and outcome are assessed at the same time. 
Consequently it is unknown if the development of the asthma truly preceded the exposure 
(e.g. LRTIs). This is a disadvantage with case-control studies (18), and for this reason the 
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present findings might not be generalizable to other children populations. Measuring post-test 
odds and post-test probability has its limitations. Both post-test odds and probability are 
depending on the pre-test odds or prevalence of the disease in question. As different 
populations have different pre-test odds and prevalence of asthma, they will experience 
different post-test probability even if similar clinical tests were used. This makes comparison 
of results between different populations and generalization challenging. Finally, the case-
control studies from 1985 and 2008 were not identical in respect of screening of variables and 
clinical testing, and this was a limitation. Thus, caution was necessary in drawing conclusions 
and in generalizing, but nonetheless we believe that the data and analysis were useful to the 







In Nordland county, repeated cross-sectional surveys between 1985 and 2008 revealed an 
increase in the prevalence of asthma and AR ever among schoolchildren (7-14 years), while 
the prevalence of eczema ever reached a plateau. The prevalence of current diseases doubled 
and trebled between 1995 and 2008. 
 
Validation of the survey questionnaire used in several studies, found it to be a valid proxy for 
clinical assessment in terms of identifying cases of asthma in schoolchildren. Within the 
limitations of our case-control study design, questions covering disease predicted asthmatic 
children better (with higher sensitivity) than those covering symptoms. Detailed clinical 
testing adds little additional information and seems unnecessary in terms of establishing 
disease prevalence for asthma. The questionnaire used seemed to be a good research tool for 
cross-sectional surveys. However, with future research one might consider removing 
questions related to symptoms to reduce the questionnaire burden. 
 
One or repeated lower respiratory tract infections during the first three years of life was 
identified to be the most important risk factor for current asthma in this subarctic child 
population when adjusting for other variables. Whether or not lower respiratory tract 
infections have contributed to the increased asthma prevalence in this population over these 
23 years is still unresolved. During the period, 1985-2008 increased average temperature may 
have led to a rise in pollen production and thereby he increased prevalence of AR. Since 
allergic comorbidity was identified as a risk factor for current asthma in 2008, AR might have 
contributed to the increased asthma prevalence in the study population. In 1985, atopic 
diseases in the family had a major impact on current asthma, but not in 2008. The contrast in 
these findings might be explained by the substantial increase in the prevalence, regarding of 
the asthma status in the child, of atopic diseases among the family members between 1985 




7. Future perspectives  
 
The results of the papers included in the present thesis raises two main questions. First: Is the 
prevalence of asthma and AR still rising in the study area? Diverse global trends in the 
prevalence of asthma and allergic diseases make regional repeated investigations important to 
assess time trends. Thus, from an epidemiological point of view the need for a follow-up 
survey in our study area after an appropriate interval is evident. A new survey will serve at 
least two purposes: 1) answer if the prevalence in asthma and allergic diseases is still 
increasing or if it has reached a plateau and 2) provide information about local conditions that 
may affect disease prevalence. The preferred design for a follow up study would be a cross-
sectional survey, using the same questionnaire as previously except for a possible 
modification of questions related to asthma symptoms. To ensure a high participation rate the 
questionnaire should be designed using an online survey software and web tools (e.g. 
Questback) making it more accessible for the study participants and their parents. An 
investigation of non-responders as well as responders would give valuable insight to whether 
or not the results from the survey could be fully generalized. 	
 
Second: Which risk factors are the most important ones when it comes to preventing asthma 
development in children? Because of the considerable burden of asthma, it is important to 
identify individual risk factors associated with childhood asthma for developing preventative 
strategies (172). As LRTIs and AR are major risk factors for the asthma development in 
children (173, 174), it is of the utmost importance for future research to focus on preventing 
strategies for LRTIs and AR. Persistent asthma might result from interactions between 
immune responses to allergens and respirator tract viruses, mainly RSV and Rhinovirus. 
Could therapeutic approaches that activate innate immune responses prevent acute viral LRIs 
and be used to prevent asthma (173)? In addition, studies has shown prednisolone treatment to 
be beneficial in subgroups of young children with high viral loads at presentation of first 
wheeze episode (175), which would be an interesting subject for further investigations. A 
recent German study revealed allergy immunotherapy (AIT) as a possible effective tool 
preventing the progression of AR to asthma in a real-life setting (176). Could AIT induce 
long term remission of asthma (177)? The preferred study design for answering these 
questions would be a prospective birth cohort, including all pregnant women from Nordland 
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county during a defined period (e.g. one year). A longitudinal design is needed to establish 
causal inferences to better understand underlying mechanisms for asthma, to identify different 
asthma phenotypes and subgroups and developing preventive strategies.  
 
In a recent comprehensive international study, children with asthma were found to have 
epigenetic (acquired) DNA changes in certain cells of the immune system (178). The findings 
in this study promise epigenetic regulation as a new treatment strategy for improved diagnosis 
and treatment for individuals. With different phenotypes and stronger focus on different 
individual subtypes, it is important in the future to include shared decision-making for people 
with asthma, including children. Research in this field so far cannot provide meaningful 
overall conclusions (179). Thus, despite the extensive research conducted, the need for new 
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 Skjema nr.  
INNLEDNING 
 
Dette er spørreskjemaet som vi ber dere fylle ut hvis dere vil delta i forskningsprosjektet. 
Spørreskjemaet inneholder 49 spørsmål. Undersøkelsen baserer seg på frivillig deltakelse, 
men for det beste resultatet, er det viktig at så mange som mulig deltar. 
 
Vi ønsker å delta i forskningsprosjektet:  Ja   
  






Gutt  Jente        Fødselsdato   
 
Skole:……………………………………………………………………………………….                 Klasse   
 
Hvor bodde eleven det første leveåret(poststed)?.................................................................................... 
 
Hvor lenge har eleven bodd i nåværende område (antall år)?  
Spørreskjemaet er fylt ut av: 





 1. Har noen i familien til eleven (foreldre, søsken) hatt astma, ”høysnue”,  
     eksem, elveblest eller andre sykdommer som dere tror kan skyldes allergi?  Ja  Nei  
 2. Hvis JA: kryss av:  
 Mor Far Søstere Brødre 
Astma     
Høysnue     
Elveblest     
Eksem     
Andre allergiske sykdommer     
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 4. Har eleven hatt astma?                            Ja  Nei  
 5. Hvis JA: har eleven hatt slike plager siste 12 måneder?  Ja  Nei  
 
  
 6. Har eleven brukt astmamedisiner? Ja  Nei  
 7. Hvis JA: har eleven brukt slike medisiner siste 12 måneder?  Ja  Nei   
 8. Har lege diagnostisert astma hos eleven?  Ja  Nei  
 9. Har eleven hatt perioder med tetthet og piping i brystet, 
      og/eller anfall med tung pust uten at dette har vært 
      oppfattet som astma?  Ja  Nei  
10. Har eleven hatt perioder med hoste uten å være forkjølet?  Ja  Nei  
11. Har eleven hatt anfall med tung pust?  Ja  Nei  
12. Får eleven piping i brystet eller blir han/hun mer tungpustet 
      enn jevnaldrende ved anstrengelser eller i rå, kald luft?  Ja  Nei  
 
13. Får eleven piping i brystet, perioder med hoste eller anfall 
      med tung pust (astma) på grunn av ytre faktorer?  Ja  Nei  
 
 
14. Hvis JA: kryss av: 
Dyr  Gress  Matvarer  
Værforandringer  Infeksjoner  Andre  
 
15. Har eleven noen gang vært behandlet av lege eller innlagt i  
      i sykehus for annen sykdom enn nevnt ovenfor i bronkier  





16. Har eleven hatt ”høysnue”( Perioder med plager fra nese og/eller 
      øynene som f. eks renning fra nesen, nesetetthet, nysing,  
      kløe i nese/øyne, hovne øyne, ”røde øyne”)?  Ja  Nei  
 
 
17. Hvis JA: har eleven hatt slike plager siste 12 måneder?  Ja  Nei  
 
Hvis NEI: fortsett til spørsmål nr. 27. 
  
18. Hvis JA: kryss av:  
Nesetetthet     Renning fra nesen     Kløe i nesen  
Kløe i øynene  Hovne øyne  Nysing  
Hevelse rundt øynene  Rødhet i øynene  Andre  
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19. Vet dere om forhold som utløser høysnueplagene?  Ja  Nei  
20. Hvis JA: kryss av: 
Dyrekontakt  Gress  Trær  
Matvarer  Andre    
 
21. Er det noen årstid hvor høysnueplagene er verst?  Ja  Nei  
22. Hvis JA: kryss av: 
Sommer  Høst  
Vinter  Vår  
 
23. Hva var elevens alder (år) da høysnueplagene begynte?   
24. Dersom eleven tidligere har hatt høysnue, men nå er kvitt 
      disse plagene: Hvor gammel var eleven da plagene forsvant?      
 
25. Bruker eleven medisiner for sine høysnue plager?  Ja  Nei   
26. Hvis JA: hvilke medisner bruker han/hun? 





27. Har eleven hatt utslett som har vart i mer enn 4 uker?  Ja  Nei  
 
Hvis NEI: fortsett til spørsmål nr. 32. 
 
28. Hvis JA: har eleven hatt slikt utslett siste 12 måneder? Ja  Nei  
 
 
29. Hvis JA: med:  
Mye kløe  Lite kløe  Ingen kløe  
 
30. Hvis JA: hvor var utslettet lokalisert? 
Ansikt  Mage  Albuebøyer  
Rygg  Knehaser  Andre steder  
 
31. Hvis JA: hvor gammel var eleven da utslettet begynte   
32. Dersom eleven tidligere har hatt utslett som ovenfor nevnt, 
      men nå er kvitt plagene: Hvor gammel var han/hun da utslettet  
      forsvant?  
33. Har eleven hatt elveblest (kløe og hevelse i huden – utslettet 
      flytter seg fra sted til sted ila minutter/timer og forsvinner 
      etter timer eller dager)?  Ja  Nei  
 
Hvis NEI: fortsett til spørsmål nr. 36.  
 
34. Hvis JA: hvor mange slike perioder har eleven hatt? 
Mindre enn 5  Flere enn 5  
 
35. Hvis JA: hvor gammel var han/hun da plagene begynte?  
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36. Har eleven reagert på matvarer?  Ja  Nei  
 
Hvis NEI: fortsett til spørsmål nr. 40. 
 
37. Hvis JA: 
Bare en gang  Flere ganger  
 
38. Hvis JA: hvordan reagerte han/hun? 
Kløe i halsen  Tungpust  
Utslett/elveblest  Allergisjokk  
 
39. Hvis JA: hva reagerte han/hun på? 




40. Hvor mange i familien bor nå sammen?  
41. I hvilket år ble boligen bygget?  
42. Hvor stor er boligen (ca boligareal i kvadratmeter)?            
 
43. Ligger boligen i et tettbebygget område med gater? Ja  Nei  
44. Ligger skolen så langt unna hjemstedet at eleven må ha skyss til skolen?  Ja  Nei  
45. Røyker noen i familien daglig?  Ja  Nei  
46. Røyker noen i familien innendørs? Ja  Nei  
47. Har familien selv dyr? Ja  Nei  
48. Hvis JA: hvilke: 
Hund  Katt  Hest  
Ku  Geit  Reinsdyr  
Sau  Kanin  Fugl (er)  
Marsvin  Hamster  Andre  
 
49. Hvis NEI: har eleven omtrent daglig kontakt med dyr?  Ja  Nei  
 
Vi ber dere om å se over at alle spørsmål som dere ønsker å besvare, er besvart. Spesielt 
viktig er det at spørsmålene uthevet med gult er besvart. Vi sender ut spørreskjemaet på 
nytt etter ca 3 uker for de som ikke da har svart. De som svarte ved første henvendelse, 
kan se bort fra andre gangs utsendelse.  
Noen elever som har astma, og en kontroll for hver slik elev, vil senere bli invitert til en 
nærmere undersøkelse med testing. De dette gjelder, vil få nærmere informasjon om den 
planlagte oppfølgningsundersøkelsen, og det er frivillig om man vil delta. 
 
Tillater foreldre/foresatte at vi tar kontakt med informasjon om oppfølgnings-
undersøkelsen dersom deres barn blir valgt ut til dette?  Ja  Nei  
 
 
TUSEN TAKK FOR HJELPEN! 
